You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創醫療(00853.HK):心脈醫療2021年預計淨利同比增加40%-50%
格隆匯 01-24 21:46

格隆匯1月24日丨微創醫療(00853.HK)公吿,心脈醫療科技為一家於科創板上市公司。於公吿日期,公司持有心脈醫療科技已發行股本約46.34%及其業績與公司財務業績綜合入賬。

心脈醫療預計2021年年度實現歸屬於母公司所有者的淨利潤為3億元到3.2億元,與上年同期相比,將增加8585萬元到1.07億元,同比增加40%到50%。

報吿期內雖然新冠疫情有所反覆,對相關手術的開展產生一定影響,但是公司的創新性產品包括Castor分支型主動脈覆膜支架及輸送系統、Minos腹主動脈覆膜支架及輸送系統、Reewarm PTX藥物球囊擴張導管等新產品在報吿期內仍持續獲得快速增長,上述產品進一步鞏固和提高了公司在主動脈及外周血管介入市場的競爭力。同時,隨着公司創新性產品在國際市場的開拓力度不斷加大,海外業務收入亦獲得快速增長。

另外,報吿期公司繼續堅持技術研發和創新能力建設,進一步加大對創新性產品的研發投入,研發投入較2020年度有較大幅度增長,同時報吿期內公司實施股權激勵計劃,產生股權激勵費用近500萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account